<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01763827</url>
  </required_header>
  <id_info>
    <org_study_id>20110114</org_study_id>
    <nct_id>NCT01763827</nct_id>
  </id_info>
  <brief_title>Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2</brief_title>
  <acronym>MENDEL-2</acronym>
  <official_title>A Double-blind, Randomized, Placebo and Ezetimibe-controlled, Multicenter Study to Evaluate Safety and Efficacy of Lipid Lowering Monotherapy With AMG 145 in Subjects With a 10-Year Framingham Risk Score of 10% or Less</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective was to evaluate the effect of 12 weeks of evolocumab subcutaneous (SC)
      monotherapy every 2 weeks (Q2W) and monthly (QM), compared with placebo and ezetimibe, on
      percent change from baseline in low-density lipoprotein cholesterol (LDL-C) in adults with a
      10-year Framingham risk score of 10% or less.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12</measure>
    <time_frame>Baseline and Weeks 10 and 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in LDL-C at the Mean of Weeks 10 and 12</measure>
    <time_frame>Baseline and Weeks 10 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in LDL-C at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieved a Mean LDL-C at Weeks 10 and 12 of Less Than 70 mg/dL</measure>
    <time_frame>Weeks 10 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieved LDL-C &lt; 70 mg/dL at Week 12</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) at the Mean of Weeks 10 and 12</measure>
    <time_frame>Baseline and Weeks 10 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Non-HDL-C at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Apolipoprotein B at the Mean of Weeks 10 and 12</measure>
    <time_frame>Baseline and Weeks 10 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Apolipoprotein B at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Total Cholesterol/High Density Lipoprotein-cholesterol Ratio at the Mean of Weeks 10 and 12</measure>
    <time_frame>Baseline and Weeks 10 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Total Cholesterol/High Density Lipoprotein-cholesterol Ratio at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at the Mean of Weeks 10 and 12</measure>
    <time_frame>Baseline and Weeks 10 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Lipoprotein (a) at the Mean of Weeks 10 and 12</measure>
    <time_frame>Baseline and Weeks 10 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Lipoprotein (a) at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Triglycerides at the Mean of Weeks 10 and 12</measure>
    <time_frame>Baseline and Weeks 10 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Triglycerides at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Very Low Density Lipoprotein Cholesterol (VLDL-C) at the Mean of Weeks 10 and 12</measure>
    <time_frame>Baseline and Weeks 10 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in VLDL-C at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C) at the Mean of Weeks 10 and 12</measure>
    <time_frame>Baseline and Weeks 10 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in HDL-C at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">615</enrollment>
  <condition>Hyperlipidemia</condition>
  <arm_group>
    <arm_group_label>Placebo Q2W</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received placebo subcutaneous injection once every 2 weeks (Q2W) and placebo tablets once a day for up to 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo QM</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received placebo subcutaneous injection once every month (QM) and placebo tablets once a day for up to 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ezetimibe (Q2W)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ezetimibe (QM)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Evolocumab Q2W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Evolocumab QM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for up to 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Evolocumab</intervention_name>
    <description>Administered by subcutaneous injection</description>
    <arm_group_label>Evolocumab Q2W</arm_group_label>
    <arm_group_label>Evolocumab QM</arm_group_label>
    <other_name>AMG 145</other_name>
    <other_name>Repatha</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ezetimibe</intervention_name>
    <description>Administered orally once a day</description>
    <arm_group_label>Ezetimibe (Q2W)</arm_group_label>
    <arm_group_label>Ezetimibe (QM)</arm_group_label>
    <other_name>Zetia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo to Evolocumab</intervention_name>
    <description>Administered by subcutaneous injection</description>
    <arm_group_label>Placebo Q2W</arm_group_label>
    <arm_group_label>Placebo QM</arm_group_label>
    <arm_group_label>Ezetimibe (Q2W)</arm_group_label>
    <arm_group_label>Ezetimibe (QM)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo to Ezetimibe</intervention_name>
    <description>Administered orally once daily</description>
    <arm_group_label>Placebo Q2W</arm_group_label>
    <arm_group_label>Placebo QM</arm_group_label>
    <arm_group_label>Evolocumab Q2W</arm_group_label>
    <arm_group_label>Evolocumab QM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female ≥ 18 to ≤ 80 years of age

          -  National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III)
             Framingham risk score of 10% or less

          -  Fasting LDL-C ≥ 100 mg/dL (2.6 mmol/L) and &lt;190 mg/dL

          -  Fasting triglycerides ≤ 400 mg/dL (4.5 mmol/L)

        Exclusion Criteria:

          -  History of coronary heart disease

          -  New York Heart Association (NYHA) III or IV heart failure

          -  Uncontrolled cardiac arrhythmia

          -  Uncontrolled hypertension

          -  Diabetes mellitus (Type 1 diabetes, poorly controlled type 2 diabetes)

          -  Uncontrolled hypothyroidism or hyperthyroidism
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Carmichael</city>
        <state>California</state>
        <zip>95608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <zip>92024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <zip>92780</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ponte Vedra</city>
        <state>Florida</state>
        <zip>32081</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sanford</city>
        <state>Florida</state>
        <zip>32771</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60654</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brockton</city>
        <state>Massachusetts</state>
        <zip>02301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <zip>55435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Olive Branch</city>
        <state>Mississippi</state>
        <zip>38654</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89148</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Endwell</city>
        <state>New York</state>
        <zip>13760</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Windsor</city>
        <state>New York</state>
        <zip>12553</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44311</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Norman</city>
        <state>Oklahoma</state>
        <zip>73069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mt. Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boerne</city>
        <state>Texas</state>
        <zip>78006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Renton</city>
        <state>Washington</state>
        <zip>98057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Maroubra</city>
        <state>New South Wales</state>
        <zip>2035</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Carina Heights</city>
        <state>Queensland</state>
        <zip>4152</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sherwood</city>
        <state>Queensland</state>
        <zip>4075</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Anthée</city>
        <zip>5520</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>1080</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gozee</city>
        <zip>6534</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gribomont</city>
        <zip>6887</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Halen</city>
        <zip>3545</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ham</city>
        <zip>3945</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Linkebeek</city>
        <zip>1630</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Retie</city>
        <zip>2470</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tessenderlo</city>
        <zip>3980</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bay Roberts</city>
        <state>Newfoundland and Labrador</state>
        <zip>A0A 1G0</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mount Pearl</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1N 1W7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M9W 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Granby</city>
        <state>Quebec</state>
        <zip>J2G 8Z9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aalborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ballerup</city>
        <zip>2750</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vejle</city>
        <zip>7100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gières</city>
        <zip>38610</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Grenoble Cedex 9</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Alberton</city>
        <state>Gauteng</state>
        <zip>1449</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>2196</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Parow</city>
        <state>Western Cape</state>
        <zip>7505</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Somerset West</city>
        <state>Western Cape</state>
        <zip>7130</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Worcester</city>
        <state>Western Cape</state>
        <zip>6850</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bloemfontein</city>
        <zip>9301</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kaohsiung</city>
        <zip>807</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kaohsiung</city>
        <zip>83301</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Istanbul</city>
        <zip>34093</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Istanbul</city>
        <zip>34662</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Korea, Republic of</country>
    <country>South Africa</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <reference>
    <citation>Koren MJ, Lundqvist P, Bolognese M, Neutel JM, Monsalvo ML, Yang J, Kim JB, Scott R, Wasserman SM, Bays H; MENDEL-2 Investigators. Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab. J Am Coll Cardiol. 2014 Jun 17;63(23):2531-2540. doi: 10.1016/j.jacc.2014.03.018. Epub 2014 Mar 29.</citation>
    <PMID>24691094</PMID>
  </reference>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 7, 2013</study_first_submitted>
  <study_first_submitted_qc>January 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2013</study_first_posted>
  <results_first_submitted>August 28, 2015</results_first_submitted>
  <results_first_submitted_qc>November 25, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 30, 2015</results_first_posted>
  <disposition_first_submitted>May 6, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>May 6, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 21, 2014</disposition_first_posted>
  <last_update_submitted>November 25, 2015</last_update_submitted>
  <last_update_submitted_qc>November 25, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>High cholesterol, Treatment for high cholesterol, Lowering cholesterol, Lowering high cholesterol, Hypercholesterolemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ezetimibe</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Men and women ≥ 18 to ≤ 80 years of age with fasting low-density lipoprotein cholesterol (LDL-C) ≥ 100 mg/dL and &lt; 190 mg/dL and fasting triglycerides ≤ 400 mg/dL with a 10-year Framingham Risk Score of 10% or less were eligible for this study. The first participant was enrolled on 21 January 2013 and the last participant was enrolled 29 July 2013.</recruitment_details>
      <pre_assignment_details>Participants received subcutaneous placebo corresponding to the once monthly dose volume during a 6 week screening period. Participants who completed the screening period and met final eligibility criteria were randomized 1:1:1:1:2:2 into 6 treatment groups. Randomization was stratified by LDL-C concentration (&lt; 130 mg/dL or ≥ 30 mg/dL).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo Q2W</title>
          <description>Participants received placebo subcutaneous injection once every 2 weeks (Q2W) and placebo tablets once a day for up to 12 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Placebo QM</title>
          <description>Participants received placebo subcutaneous injection once every month (QM) and placebo tablets once a day for up to 12 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Ezetimibe (Q2W)</title>
          <description>Participants received placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
        </group>
        <group group_id="P4">
          <title>Ezetimibe (QM)</title>
          <description>Participants received placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
        </group>
        <group group_id="P5">
          <title>Evolocumab Q2W</title>
          <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.</description>
        </group>
        <group group_id="P6">
          <title>Evolocumab QM</title>
          <description>Participants received 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for up to 12 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="77"/>
                <participants group_id="P2" count="78"/>
                <participants group_id="P3" count="77"/>
                <participants group_id="P4" count="77"/>
                <participants group_id="P5" count="153"/>
                <participants group_id="P6" count="153"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least 1 Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="76"/>
                <participants group_id="P2" count="78"/>
                <participants group_id="P3" count="77"/>
                <participants group_id="P4" count="77"/>
                <participants group_id="P5" count="153"/>
                <participants group_id="P6" count="153"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="74"/>
                <participants group_id="P2" count="77"/>
                <participants group_id="P3" count="73"/>
                <participants group_id="P4" count="76"/>
                <participants group_id="P5" count="147"/>
                <participants group_id="P6" count="151"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Decision by sponsor</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo Q2W</title>
          <description>Participants received placebo subcutaneous injection once every 2 weeks (Q2W) and placebo tablets once a day for up to 12 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Placebo QM</title>
          <description>Participants received placebo subcutaneous injection once every month (QM) and placebo tablets once a day for up to 12 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Ezetimibe (Q2W)</title>
          <description>Participants received placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Ezetimibe (QM)</title>
          <description>Participants received placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
        </group>
        <group group_id="B5">
          <title>Evolocumab Q2W</title>
          <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.</description>
        </group>
        <group group_id="B6">
          <title>Evolocumab QM</title>
          <description>Participants received 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for up to 12 weeks.</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="77"/>
            <count group_id="B2" value="78"/>
            <count group_id="B3" value="77"/>
            <count group_id="B4" value="77"/>
            <count group_id="B5" value="153"/>
            <count group_id="B6" value="153"/>
            <count group_id="B7" value="615"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.4" spread="10.3"/>
                    <measurement group_id="B2" value="52.6" spread="10.7"/>
                    <measurement group_id="B3" value="53.9" spread="11.3"/>
                    <measurement group_id="B4" value="53.0" spread="12.7"/>
                    <measurement group_id="B5" value="52.5" spread="13.7"/>
                    <measurement group_id="B6" value="52.9" spread="12.1"/>
                    <measurement group_id="B7" value="53.1" spread="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="53"/>
                    <measurement group_id="B4" value="52"/>
                    <measurement group_id="B5" value="104"/>
                    <measurement group_id="B6" value="101"/>
                    <measurement group_id="B7" value="406"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="49"/>
                    <measurement group_id="B6" value="52"/>
                    <measurement group_id="B7" value="209"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="12"/>
                    <measurement group_id="B7" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="9"/>
                    <measurement group_id="B7" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="63"/>
                    <measurement group_id="B4" value="60"/>
                    <measurement group_id="B5" value="132"/>
                    <measurement group_id="B6" value="129"/>
                    <measurement group_id="B7" value="511"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mixed Race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="14"/>
                    <measurement group_id="B6" value="21"/>
                    <measurement group_id="B7" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="68"/>
                    <measurement group_id="B4" value="66"/>
                    <measurement group_id="B5" value="139"/>
                    <measurement group_id="B6" value="132"/>
                    <measurement group_id="B7" value="546"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Stratification Factor: Low-density Lipoprotein Cholesterol (LDL-C)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 130 mg/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="22"/>
                    <measurement group_id="B5" value="45"/>
                    <measurement group_id="B6" value="45"/>
                    <measurement group_id="B7" value="181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 130 mg/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="55"/>
                    <measurement group_id="B4" value="55"/>
                    <measurement group_id="B5" value="108"/>
                    <measurement group_id="B6" value="108"/>
                    <measurement group_id="B7" value="434"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>LDL-C Concentration</title>
          <description>Data are provided for the full analysis set (all randomized participants who received at least 1 dose of investigational product (subcutaneously or orally).</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="139.5" spread="21.3"/>
                    <measurement group_id="B2" value="144.3" spread="23.9"/>
                    <measurement group_id="B3" value="143.3" spread="23.8"/>
                    <measurement group_id="B4" value="143.5" spread="23.1"/>
                    <measurement group_id="B5" value="141.7" spread="22.3"/>
                    <measurement group_id="B6" value="144.4" spread="23.3"/>
                    <measurement group_id="B7" value="142.9" spread="22.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) Concentration</title>
          <description>Data are provided for the full analysis set</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="167.4" spread="25.8"/>
                    <measurement group_id="B2" value="172.8" spread="31.0"/>
                    <measurement group_id="B3" value="168.8" spread="28.9"/>
                    <measurement group_id="B4" value="169.4" spread="27.3"/>
                    <measurement group_id="B5" value="166.5" spread="25.6"/>
                    <measurement group_id="B6" value="170.4" spread="26.6"/>
                    <measurement group_id="B7" value="169.0" spread="27.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Apolipoprotein B Concentration</title>
          <description>Data are provided for the full analysis set</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="103.7" spread="16.8"/>
                    <measurement group_id="B2" value="107.3" spread="19.9"/>
                    <measurement group_id="B3" value="107.2" spread="19.7"/>
                    <measurement group_id="B4" value="106.2" spread="17.8"/>
                    <measurement group_id="B5" value="104.5" spread="17.2"/>
                    <measurement group_id="B6" value="108.3" spread="17.9"/>
                    <measurement group_id="B7" value="106.2" spread="18.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total Cholesterol/High-density Lipoprotein Cholesterol Ratio</title>
          <description>Data are provided for the full analysis set</description>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.148" spread="1.311"/>
                    <measurement group_id="B2" value="4.444" spread="1.465"/>
                    <measurement group_id="B3" value="4.055" spread="1.082"/>
                    <measurement group_id="B4" value="4.335" spread="1.118"/>
                    <measurement group_id="B5" value="4.170" spread="1.170"/>
                    <measurement group_id="B6" value="4.175" spread="1.071"/>
                    <measurement group_id="B7" value="4.210" spread="1.191"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Apolipoprotein B/Apolipoprotein A-1 Ratio</title>
          <description>Data are provided for the full analysis set</description>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.671" spread="0.193"/>
                    <measurement group_id="B2" value="0.713" spread="0.194"/>
                    <measurement group_id="B3" value="0.691" spread="0.187"/>
                    <measurement group_id="B4" value="0.712" spread="0.173"/>
                    <measurement group_id="B5" value="0.687" spread="0.169"/>
                    <measurement group_id="B6" value="0.707" spread="0.170"/>
                    <measurement group_id="B7" value="0.697" spread="0.178"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lipoprotein(a)</title>
          <description>Data are provided for the full analysis set</description>
          <units>nmol/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21.0" spread="62.9" lower_limit="9.0" upper_limit="49.0"/>
                    <measurement group_id="B2" value="21.5" spread="84.0" lower_limit="7.0" upper_limit="62.0"/>
                    <measurement group_id="B3" value="28.0" spread="79.1" lower_limit="11.0" upper_limit="120.0"/>
                    <measurement group_id="B4" value="28.0" spread="65.7" lower_limit="12.0" upper_limit="64.0"/>
                    <measurement group_id="B5" value="20.0" spread="61.5" lower_limit="7.0" upper_limit="58.0"/>
                    <measurement group_id="B6" value="28.0" spread="86.9" lower_limit="9.0" upper_limit="104.0"/>
                    <measurement group_id="B7" value="25.0" spread="74.5" lower_limit="9.0" upper_limit="71.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Triglycerides</title>
          <description>Data are provided for the full analysis set</description>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="113.5" spread="74.7" lower_limit="83.3" upper_limit="178.0"/>
                    <measurement group_id="B2" value="118.0" spread="83.4" lower_limit="85.5" upper_limit="178.5"/>
                    <measurement group_id="B3" value="112.5" spread="64.9" lower_limit="83.5" upper_limit="158.0"/>
                    <measurement group_id="B4" value="116.5" spread="52.4" lower_limit="90.0" upper_limit="159.0"/>
                    <measurement group_id="B5" value="112.0" spread="62.6" lower_limit="81.5" upper_limit="147.5"/>
                    <measurement group_id="B6" value="119.0" spread="59.1" lower_limit="82.5" upper_limit="168.5"/>
                    <measurement group_id="B7" value="115.3" spread="65.5" lower_limit="83.5" upper_limit="163.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Very Low-density Lipoprotein Cholesterol (VLDL-C) Concentration</title>
          <description>Data are provided for the full analysis set</description>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22.5" spread="13.2" lower_limit="16.8" upper_limit="34.3"/>
                    <measurement group_id="B2" value="23.8" spread="15.4" lower_limit="17.0" upper_limit="35.5"/>
                    <measurement group_id="B3" value="22.5" spread="12.4" lower_limit="16.5" upper_limit="32.0"/>
                    <measurement group_id="B4" value="23.5" spread="10.5" lower_limit="18.0" upper_limit="31.5"/>
                    <measurement group_id="B5" value="22.5" spread="11.5" lower_limit="16.5" upper_limit="29.5"/>
                    <measurement group_id="B6" value="23.5" spread="11.8" lower_limit="16.5" upper_limit="33.5"/>
                    <measurement group_id="B7" value="23.0" spread="12.4" lower_limit="16.5" upper_limit="32.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>High-density Lipoprotein Cholesterol (HDL-C) Concentration</title>
          <description>Data are provided for the full analysis set</description>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.0" spread="23.6" lower_limit="43.8" upper_limit="77.3"/>
                    <measurement group_id="B2" value="54.0" spread="17.8" lower_limit="44.5" upper_limit="65.5"/>
                    <measurement group_id="B3" value="58.5" spread="16.8" lower_limit="47.0" upper_limit="69.5"/>
                    <measurement group_id="B4" value="53.5" spread="18.5" lower_limit="42.0" upper_limit="67.5"/>
                    <measurement group_id="B5" value="53.0" spread="18.0" lower_limit="44.5" upper_limit="67.0"/>
                    <measurement group_id="B6" value="56.5" spread="18.0" lower_limit="46.5" upper_limit="65.5"/>
                    <measurement group_id="B7" value="55.3" spread="18.7" lower_limit="44.5" upper_limit="67.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 12</title>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Q2W</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks (Q2W) and placebo tablets once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo QM</title>
            <description>Participants received placebo subcutaneous injection once every month (QM) and placebo tablets once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Ezetimibe (Q2W)</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Ezetimibe (QM)</title>
            <description>Participants received placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Evolocumab Q2W</title>
            <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Evolocumab QM</title>
            <description>Participants received 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 12</title>
          <population>Full analysis set</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="77"/>
                <count group_id="O4" value="77"/>
                <count group_id="O5" value="153"/>
                <count group_id="O6" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.10" spread="1.67"/>
                    <measurement group_id="O2" value="-1.34" spread="1.54"/>
                    <measurement group_id="O3" value="-17.75" spread="1.67"/>
                    <measurement group_id="O4" value="-18.57" spread="1.56"/>
                    <measurement group_id="O5" value="-57.04" spread="1.23"/>
                    <measurement group_id="O6" value="-56.12" spread="1.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there was no mean difference in the percent change from Baseline at Week 12 in LDL-C between evolocumab and placebo, and the alternative hypothesis was that a mean difference did exist.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, Baseline LDL-C level, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-57.14</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.03</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-61.14</ci_lower_limit>
            <ci_upper_limit>-53.14</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there was no mean difference in the percent change from Baseline at Week 12 in LDL-C between evolocumab and placebo, and the alternative hypothesis was that a mean difference did exist.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, Baseline LDL-C level, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-54.78</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.87</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-58.46</ci_lower_limit>
            <ci_upper_limit>-51.10</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there was no mean difference in the percent change from Baseline at Week 12 in LDL-C between evolocumab and ezetimibe, and the alternative hypothesis was that a mean difference did exist.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, Baseline LDL-C level, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-39.29</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.03</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-43.28</ci_lower_limit>
            <ci_upper_limit>-35.31</ci_upper_limit>
            <estimate_desc>Ezetimibe is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there was no mean difference in the percent change from Baseline at Week 12 in LDL-C between evolocumab and ezetimibe, and the alternative hypothesis was that a mean difference did exist.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, Baseline LDL-C level, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-37.55</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.88</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-41.24</ci_lower_limit>
            <ci_upper_limit>-33.86</ci_upper_limit>
            <estimate_desc>Ezetimibe is the reference</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12</title>
        <time_frame>Baseline and Weeks 10 and 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Q2W</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks (Q2W) and placebo tablets once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo QM</title>
            <description>Participants received placebo subcutaneous injection once every month (QM) and placebo tablets once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Ezetimibe (Q2W)</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Ezetimibe (QM)</title>
            <description>Participants received placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Evolocumab Q2W</title>
            <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Evolocumab QM</title>
            <description>Participants received 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12</title>
          <population>Full analysis set</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="77"/>
                <count group_id="O4" value="77"/>
                <count group_id="O5" value="153"/>
                <count group_id="O6" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.43" spread="1.45"/>
                    <measurement group_id="O2" value="-1.41" spread="1.37"/>
                    <measurement group_id="O3" value="-17.52" spread="1.46"/>
                    <measurement group_id="O4" value="-19.12" spread="1.39"/>
                    <measurement group_id="O5" value="-56.93" spread="1.07"/>
                    <measurement group_id="O6" value="-58.81" spread="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there was no mean difference in the percent change from Baseline at the mean of Weeks 10 and 12 in LDL-C between evolocumab and placebo, and the alternative hypothesis was that a mean difference did exist.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, Baseline LDL-C level, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-56.50</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.76</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-59.95</ci_lower_limit>
            <ci_upper_limit>-53.04</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there was no mean difference in the percent change from Baseline at the mean of Weeks 10 and 12 in LDL-C between evolocumab and placebo, and the alternative hypothesis was that a mean difference did exist.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, Baseline LDL-C level, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-57.40</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.66</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-60.66</ci_lower_limit>
            <ci_upper_limit>-54.14</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there was no mean difference in the percent change from Baseline at the mean of Weeks 10 and 12 in LDL-C between evolocumab and ezetimibe, and the alternative hypothesis was that a mean difference did exist.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, Baseline LDL-C level, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-39.41</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.76</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-42.87</ci_lower_limit>
            <ci_upper_limit>-35.94</ci_upper_limit>
            <estimate_desc>Ezetimibe is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there was no mean difference in the percent change from Baseline at the mean of Weeks 10 and 12 in LDL-C between evolocumab and ezetimibe, and the alternative hypothesis was that a mean difference did exist.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, Baseline LDL-C level, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-36.69</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.66</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-42.97</ci_lower_limit>
            <ci_upper_limit>-36.42</ci_upper_limit>
            <estimate_desc>Ezetimibe is the reference</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in LDL-C at the Mean of Weeks 10 and 12</title>
        <time_frame>Baseline and Weeks 10 and 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Q2W</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks (Q2W) and placebo tablets once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo QM</title>
            <description>Participants received placebo subcutaneous injection once every month (QM) and placebo tablets once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Ezetimibe (Q2W)</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Ezetimibe (QM)</title>
            <description>Participants received placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Evolocumab Q2W</title>
            <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Evolocumab QM</title>
            <description>Participants received 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in LDL-C at the Mean of Weeks 10 and 12</title>
          <population>Full analysis set</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="77"/>
                <count group_id="O4" value="77"/>
                <count group_id="O5" value="153"/>
                <count group_id="O6" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="2.3"/>
                    <measurement group_id="O2" value="0.0" spread="2.1"/>
                    <measurement group_id="O3" value="-23.1" spread="2.3"/>
                    <measurement group_id="O4" value="-25.9" spread="2.1"/>
                    <measurement group_id="O5" value="-78.4" spread="1.7"/>
                    <measurement group_id="O6" value="-81.9" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, Baseline LDL-C level, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-79.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.7</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-85.0</ci_lower_limit>
            <ci_upper_limit>-74.2</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, Baseline LDL-C level, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-81.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.6</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-87.0</ci_lower_limit>
            <ci_upper_limit>-76.9</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, Baseline LDL-C level, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-55.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.7</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-60.7</ci_lower_limit>
            <ci_upper_limit>-49.9</ci_upper_limit>
            <estimate_desc>Ezetimibe is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, Baseline LDL-C level, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-56.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.6</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-61.1</ci_lower_limit>
            <ci_upper_limit>-51.0</ci_upper_limit>
            <estimate_desc>Ezetimibe is the reference</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in LDL-C at Week 12</title>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Q2W</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks (Q2W) and placebo tablets once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo QM</title>
            <description>Participants received placebo subcutaneous injection once every month (QM) and placebo tablets once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Ezetimibe (Q2W)</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Ezetimibe (QM)</title>
            <description>Participants received placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Evolocumab Q2W</title>
            <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Evolocumab QM</title>
            <description>Participants received 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in LDL-C at Week 12</title>
          <population>Full analysis set</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="77"/>
                <count group_id="O4" value="77"/>
                <count group_id="O5" value="153"/>
                <count group_id="O6" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="2.5"/>
                    <measurement group_id="O2" value="-0.1" spread="2.4"/>
                    <measurement group_id="O3" value="-23.4" spread="2.5"/>
                    <measurement group_id="O4" value="-25.0" spread="2.4"/>
                    <measurement group_id="O5" value="-78.4" spread="1.9"/>
                    <measurement group_id="O6" value="-77.9" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, Baseline LDL-C level, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-80.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-86.4</ci_lower_limit>
            <ci_upper_limit>-74.3</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, Baseline LDL-C level, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-77.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.8</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-83.4</ci_lower_limit>
            <ci_upper_limit>-72.2</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, Baseline LDL-C level, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-55.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-61.1</ci_lower_limit>
            <ci_upper_limit>-49.0</ci_upper_limit>
            <estimate_desc>Ezetimibe was the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, stratification factor, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-52.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.9</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-58.5</ci_lower_limit>
            <ci_upper_limit>-47.3</ci_upper_limit>
            <estimate_desc>Ezetimibe was the reference</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Achieved a Mean LDL-C at Weeks 10 and 12 of Less Than 70 mg/dL</title>
        <time_frame>Weeks 10 and 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Q2W</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks (Q2W) and placebo tablets once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo QM</title>
            <description>Participants received placebo subcutaneous injection once every month (QM) and placebo tablets once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Ezetimibe (Q2W)</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Ezetimibe (QM)</title>
            <description>Participants received placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Evolocumab Q2W</title>
            <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Evolocumab QM</title>
            <description>Participants received 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieved a Mean LDL-C at Weeks 10 and 12 of Less Than 70 mg/dL</title>
          <population>Full analysis set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="77"/>
                <count group_id="O4" value="77"/>
                <count group_id="O5" value="153"/>
                <count group_id="O6" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="4.8"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="4.9"/>
                    <measurement group_id="O3" value="1.3" lower_limit="0.2" upper_limit="7.2"/>
                    <measurement group_id="O4" value="2.8" lower_limit="0.8" upper_limit="9.6"/>
                    <measurement group_id="O5" value="73.6" lower_limit="65.7" upper_limit="80.2"/>
                    <measurement group_id="O6" value="71.3" lower_limit="63.6" upper_limit="78.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Based on CMH test stratified by Baseline LDL-C level. For testing, non-achievement was imputed for participants with a missing value.</method_desc>
            <param_type>Treatment Difference</param_type>
            <param_value>73.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>64.4</ci_lower_limit>
            <ci_upper_limit>80.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Based on CMH test stratified by Baseline LDL-C level. For testing, non-achievement was imputed for participants with a missing value.</method_desc>
            <param_type>Treatment Difference</param_type>
            <param_value>71.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>62.2</ci_lower_limit>
            <ci_upper_limit>78.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Based on CMH test stratified by Baseline LDL-C level. For testing, non-achievement was imputed for participants with a missing value.</method_desc>
            <param_type>Treatment Difference</param_type>
            <param_value>72.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>62.4</ci_lower_limit>
            <ci_upper_limit>78.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Based on CMH test stratified by Baseline LDL-C level. For testing, non-achievement was imputed for participants with a missing value.</method_desc>
            <param_type>Treatment Difference</param_type>
            <param_value>68.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>58.3</ci_lower_limit>
            <ci_upper_limit>75.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Achieved LDL-C &lt; 70 mg/dL at Week 12</title>
        <time_frame>Week 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Q2W</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks (Q2W) and placebo tablets once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo QM</title>
            <description>Participants received placebo subcutaneous injection once every month (QM) and placebo tablets once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Ezetimibe (Q2W)</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Ezetimibe (QM)</title>
            <description>Participants received placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Evolocumab Q2W</title>
            <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Evolocumab QM</title>
            <description>Participants received 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieved LDL-C &lt; 70 mg/dL at Week 12</title>
          <population>Full analysis set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="77"/>
                <count group_id="O4" value="77"/>
                <count group_id="O5" value="153"/>
                <count group_id="O6" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" lower_limit="0.3" upper_limit="7.8"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="5.2"/>
                    <measurement group_id="O3" value="1.4" lower_limit="0.3" upper_limit="7.7"/>
                    <measurement group_id="O4" value="1.4" lower_limit="0.3" upper_limit="7.8"/>
                    <measurement group_id="O5" value="72.9" lower_limit="64.8" upper_limit="79.8"/>
                    <measurement group_id="O6" value="65.4" lower_limit="57.1" upper_limit="72.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Based on CMH test stratified by Baseline LDL-C level. For testing, non-achievement was imputed for participants with a missing value.</method_desc>
            <param_type>Treatment Difference</param_type>
            <param_value>71.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>61.2</ci_lower_limit>
            <ci_upper_limit>78.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Based on CMH test stratified by Baseline LDL-C level. For testing, non-achievement was imputed for participants with a missing value.</method_desc>
            <param_type>Treatment Difference</param_type>
            <param_value>65.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>55.6</ci_lower_limit>
            <ci_upper_limit>72.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Based on CMH test stratified by Baseline LDL-C level. For testing, non-achievement was imputed for participants with a missing value.</method_desc>
            <param_type>Treatment Difference</param_type>
            <param_value>71.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>61.3</ci_lower_limit>
            <ci_upper_limit>78.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Based on CMH test stratified by Baseline LDL-C level. For testing, non-achievement was imputed for participants with a missing value.</method_desc>
            <param_type>Treatment Difference</param_type>
            <param_value>64.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>53.5</ci_lower_limit>
            <ci_upper_limit>71.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) at the Mean of Weeks 10 and 12</title>
        <time_frame>Baseline and Weeks 10 and 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Q2W</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks (Q2W) and placebo tablets once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo QM</title>
            <description>Participants received placebo subcutaneous injection once every month (QM) and placebo tablets once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Ezetimibe (Q2W)</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Ezetimibe (QM)</title>
            <description>Participants received placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Evolocumab Q2W</title>
            <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Evolocumab QM</title>
            <description>Participants received 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) at the Mean of Weeks 10 and 12</title>
          <population>Full analysis set</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="77"/>
                <count group_id="O4" value="77"/>
                <count group_id="O5" value="153"/>
                <count group_id="O6" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.41" spread="1.34"/>
                    <measurement group_id="O2" value="1.32" spread="1.24"/>
                    <measurement group_id="O3" value="-14.64" spread="1.35"/>
                    <measurement group_id="O4" value="-16.48" spread="1.25"/>
                    <measurement group_id="O5" value="-50.22" spread="0.99"/>
                    <measurement group_id="O6" value="-51.96" spread="0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, Baseline LDL-C level, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-48.81</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.63</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-52.01</ci_lower_limit>
            <ci_upper_limit>-45.61</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, Baseline LDL-C level, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-53.28</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.50</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-56.23</ci_lower_limit>
            <ci_upper_limit>-50.33</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, Baseline LDL-C level, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-35.58</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.63</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-38.79</ci_lower_limit>
            <ci_upper_limit>-32.38</ci_upper_limit>
            <estimate_desc>Ezetimibe is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, Baseline LDL-C level, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-35.49</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.50</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-38.44</ci_lower_limit>
            <ci_upper_limit>-32.53</ci_upper_limit>
            <estimate_desc>Ezetimibe is the reference</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Non-HDL-C at Week 12</title>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Q2W</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks (Q2W) and placebo tablets once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo QM</title>
            <description>Participants received placebo subcutaneous injection once every month (QM) and placebo tablets once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Ezetimibe (Q2W)</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Ezetimibe (QM)</title>
            <description>Participants received placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Evolocumab Q2W</title>
            <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Evolocumab QM</title>
            <description>Participants received 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Non-HDL-C at Week 12</title>
          <population>Full analysis set</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="77"/>
                <count group_id="O4" value="77"/>
                <count group_id="O5" value="153"/>
                <count group_id="O6" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.31" spread="1.48"/>
                    <measurement group_id="O2" value="1.51" spread="1.38"/>
                    <measurement group_id="O3" value="-14.89" spread="1.47"/>
                    <measurement group_id="O4" value="-16.48" spread="1.39"/>
                    <measurement group_id="O5" value="-50.12" spread="1.08"/>
                    <measurement group_id="O6" value="-49.68" spread="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, Baseline LDL-C level, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-49.81</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.79</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-53.34</ci_lower_limit>
            <ci_upper_limit>-46.27</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, Baseline LDL-C level, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-51.19</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.67</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-54.49</ci_lower_limit>
            <ci_upper_limit>-47.90</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, Baseline LDL-C level, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-35.23</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.78</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-38.74</ci_lower_limit>
            <ci_upper_limit>-31.71</ci_upper_limit>
            <estimate_desc>Ezetimibe is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, Baseline LDL-C level, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-33.21</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.68</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-36.51</ci_lower_limit>
            <ci_upper_limit>-29.90</ci_upper_limit>
            <estimate_desc>Ezetimibe is the reference</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Apolipoprotein B at the Mean of Weeks 10 and 12</title>
        <time_frame>Baseline and Weeks 10 and 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Q2W</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks (Q2W) and placebo tablets once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo QM</title>
            <description>Participants received placebo subcutaneous injection once every month (QM) and placebo tablets once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Ezetimibe (Q2W)</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Ezetimibe (QM)</title>
            <description>Participants received placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Evolocumab Q2W</title>
            <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Evolocumab QM</title>
            <description>Participants received 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Apolipoprotein B at the Mean of Weeks 10 and 12</title>
          <population>Full analysis set</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="77"/>
                <count group_id="O4" value="77"/>
                <count group_id="O5" value="153"/>
                <count group_id="O6" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="1.51"/>
                    <measurement group_id="O2" value="1.54" spread="1.41"/>
                    <measurement group_id="O3" value="-13.47" spread="1.52"/>
                    <measurement group_id="O4" value="-14.75" spread="1.43"/>
                    <measurement group_id="O5" value="-47.04" spread="1.12"/>
                    <measurement group_id="O6" value="-49.39" spread="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, Baseline LDL-C level, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-47.09</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.82</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-50.67</ci_lower_limit>
            <ci_upper_limit>-43.51</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, Baseline LDL-C level, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-50.93</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.70</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-54.27</ci_lower_limit>
            <ci_upper_limit>-47.59</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, Baseline LDL-C level, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-33.57</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.82</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-37.15</ci_lower_limit>
            <ci_upper_limit>-29.99</ci_upper_limit>
            <estimate_desc>Ezetimibe is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, Baseline LDL-C level, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-34.64</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.71</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-37.99</ci_lower_limit>
            <ci_upper_limit>-31.28</ci_upper_limit>
            <estimate_desc>Ezetimibe is the reference</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Apolipoprotein B at Week 12</title>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Q2W</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks (Q2W) and placebo tablets once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo QM</title>
            <description>Participants received placebo subcutaneous injection once every month (QM) and placebo tablets once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Ezetimibe (Q2W)</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Ezetimibe (QM)</title>
            <description>Participants received placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Evolocumab Q2W</title>
            <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Evolocumab QM</title>
            <description>Participants received 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Apolipoprotein B at Week 12</title>
          <population>Full analysis set</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="77"/>
                <count group_id="O4" value="77"/>
                <count group_id="O5" value="153"/>
                <count group_id="O6" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.59" spread="1.58"/>
                    <measurement group_id="O2" value="1.84" spread="1.53"/>
                    <measurement group_id="O3" value="-13.17" spread="1.58"/>
                    <measurement group_id="O4" value="-14.02" spread="1.54"/>
                    <measurement group_id="O5" value="-47.21" spread="1.17"/>
                    <measurement group_id="O6" value="-46.59" spread="1.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, Baseline LDL-C level, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-47.81</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.91</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-51.56</ci_lower_limit>
            <ci_upper_limit>-44.05</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, Baseline LDL-C level, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-48.43</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.85</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-52.07</ci_lower_limit>
            <ci_upper_limit>-44.79</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, Baseline LDL-C level, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-34.04</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.90</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-37.78</ci_lower_limit>
            <ci_upper_limit>-30.30</ci_upper_limit>
            <estimate_desc>Ezetimibe is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, Baseline LDL-C level, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-32.57</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.85</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-36.21</ci_lower_limit>
            <ci_upper_limit>-28.92</ci_upper_limit>
            <estimate_desc>Ezetimibe is the reference</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Total Cholesterol/High Density Lipoprotein-cholesterol Ratio at the Mean of Weeks 10 and 12</title>
        <time_frame>Baseline and Weeks 10 and 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Q2W</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks (Q2W) and placebo tablets once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo QM</title>
            <description>Participants received placebo subcutaneous injection once every month (QM) and placebo tablets once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Ezetimibe (Q2W)</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Ezetimibe (QM)</title>
            <description>Participants received placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Evolocumab Q2W</title>
            <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Evolocumab QM</title>
            <description>Participants received 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Total Cholesterol/High Density Lipoprotein-cholesterol Ratio at the Mean of Weeks 10 and 12</title>
          <population>Full analysis set</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="77"/>
                <count group_id="O4" value="77"/>
                <count group_id="O5" value="153"/>
                <count group_id="O6" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.44" spread="1.29"/>
                    <measurement group_id="O2" value="6.42" spread="1.50"/>
                    <measurement group_id="O3" value="-9.14" spread="1.29"/>
                    <measurement group_id="O4" value="-11.90" spread="1.51"/>
                    <measurement group_id="O5" value="-38.49" spread="0.95"/>
                    <measurement group_id="O6" value="-39.41" spread="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, Baseline LDL-C level, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-38.93</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.56</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-42.00</ci_lower_limit>
            <ci_upper_limit>-35.86</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, Baseline LDL-C level, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-45.83</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.81</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-49.39</ci_lower_limit>
            <ci_upper_limit>-42.27</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, Baseline LDL-C level, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-29.36</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.56</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-32.43</ci_lower_limit>
            <ci_upper_limit>-26.28</ci_upper_limit>
            <estimate_desc>Ezetimibe is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, Baseline LDL-C level, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-27.51</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.81</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-31.08</ci_lower_limit>
            <ci_upper_limit>-23.94</ci_upper_limit>
            <estimate_desc>Ezetimibe is the reference</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Total Cholesterol/High Density Lipoprotein-cholesterol Ratio at Week 12</title>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Q2W</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks (Q2W) and placebo tablets once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo QM</title>
            <description>Participants received placebo subcutaneous injection once every month (QM) and placebo tablets once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Ezetimibe (Q2W)</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Ezetimibe (QM)</title>
            <description>Participants received placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Evolocumab Q2W</title>
            <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Evolocumab QM</title>
            <description>Participants received 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Total Cholesterol/High Density Lipoprotein-cholesterol Ratio at Week 12</title>
          <population>Full analysis set</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="77"/>
                <count group_id="O4" value="77"/>
                <count group_id="O5" value="153"/>
                <count group_id="O6" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.18" spread="1.39"/>
                    <measurement group_id="O2" value="7.02" spread="1.67"/>
                    <measurement group_id="O3" value="-10.03" spread="1.39"/>
                    <measurement group_id="O4" value="-12.34" spread="1.68"/>
                    <measurement group_id="O5" value="-38.45" spread="1.02"/>
                    <measurement group_id="O6" value="-37.65" spread="1.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, Baseline LDL-C level, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-39.63</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.69</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-42.97</ci_lower_limit>
            <ci_upper_limit>-36.30</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, Baseline LDL-C level, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-44.67</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.03</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-48.66</ci_lower_limit>
            <ci_upper_limit>-40.68</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, Baseline LDL-C level, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-28.42</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.68</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-31.73</ci_lower_limit>
            <ci_upper_limit>-25.10</ci_upper_limit>
            <estimate_desc>Ezetimibe is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, Baseline LDL-C level, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-25.31</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.03</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-29.31</ci_lower_limit>
            <ci_upper_limit>-21.31</ci_upper_limit>
            <estimate_desc>Ezetimibe is the reference</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at the Mean of Weeks 10 and 12</title>
        <time_frame>Baseline and Weeks 10 and 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Q2W</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks (Q2W) and placebo tablets once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo QM</title>
            <description>Participants received placebo subcutaneous injection once every month (QM) and placebo tablets once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Ezetimibe (Q2W)</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Ezetimibe (QM)</title>
            <description>Participants received placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Evolocumab Q2W</title>
            <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Evolocumab QM</title>
            <description>Participants received 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at the Mean of Weeks 10 and 12</title>
          <population>Full analysis set</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="77"/>
                <count group_id="O4" value="77"/>
                <count group_id="O5" value="153"/>
                <count group_id="O6" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.01" spread="1.69"/>
                    <measurement group_id="O2" value="3.85" spread="1.77"/>
                    <measurement group_id="O3" value="-13.39" spread="1.69"/>
                    <measurement group_id="O4" value="-14.49" spread="1.79"/>
                    <measurement group_id="O5" value="-48.12" spread="1.25"/>
                    <measurement group_id="O6" value="-51.10" spread="1.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, Baseline LDL-C level, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-49.12</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.03</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-53.12</ci_lower_limit>
            <ci_upper_limit>-45.12</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, Baseline LDL-C level, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-54.95</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.12</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-59.12</ci_lower_limit>
            <ci_upper_limit>-50.78</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, Baseline LDL-C level, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-34.73</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.03</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-38.73</ci_lower_limit>
            <ci_upper_limit>-30.73</ci_upper_limit>
            <estimate_desc>Ezetimibe is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, Baseline LDL-C level, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-36.62</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.13</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-40.81</ci_lower_limit>
            <ci_upper_limit>-32.42</ci_upper_limit>
            <estimate_desc>Ezetimibe is the reference</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at Week 12</title>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Q2W</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks (Q2W) and placebo tablets once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo QM</title>
            <description>Participants received placebo subcutaneous injection once every month (QM) and placebo tablets once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Ezetimibe (Q2W)</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Ezetimibe (QM)</title>
            <description>Participants received placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Evolocumab Q2W</title>
            <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Evolocumab QM</title>
            <description>Participants received 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at Week 12</title>
          <population>Full analysis set</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="77"/>
                <count group_id="O4" value="77"/>
                <count group_id="O5" value="153"/>
                <count group_id="O6" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.12" spread="1.77"/>
                    <measurement group_id="O2" value="4.51" spread="1.90"/>
                    <measurement group_id="O3" value="-12.69" spread="1.77"/>
                    <measurement group_id="O4" value="-14.29" spread="1.92"/>
                    <measurement group_id="O5" value="-48.45" spread="1.31"/>
                    <measurement group_id="O6" value="-48.26" spread="1.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, Baseline LDL-C level, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-49.57</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.14</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-53.78</ci_lower_limit>
            <ci_upper_limit>-45.36</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, Baseline LDL-C level, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-52.77</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.29</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-57.28</ci_lower_limit>
            <ci_upper_limit>-48.26</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, Baseline LDL-C level, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-35.76</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.13</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-39.95</ci_lower_limit>
            <ci_upper_limit>-31.57</ci_upper_limit>
            <estimate_desc>Ezetimibe is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, Baseline LDL-C level, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-33.97</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.29</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-38.48</ci_lower_limit>
            <ci_upper_limit>-29.45</ci_upper_limit>
            <estimate_desc>Ezetimibe is the reference</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Lipoprotein (a) at the Mean of Weeks 10 and 12</title>
        <time_frame>Baseline and Weeks 10 and 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Q2W</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks (Q2W) and placebo tablets once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo QM</title>
            <description>Participants received placebo subcutaneous injection once every month (QM) and placebo tablets once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Ezetimibe (Q2W)</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Ezetimibe (QM)</title>
            <description>Participants received placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Evolocumab Q2W</title>
            <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Evolocumab QM</title>
            <description>Participants received 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Lipoprotein (a) at the Mean of Weeks 10 and 12</title>
          <population>Full analysis set</population>
          <units>percent change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="77"/>
                <count group_id="O4" value="77"/>
                <count group_id="O5" value="153"/>
                <count group_id="O6" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" spread="2.72" lower_limit="-11.11" upper_limit="11.50"/>
                    <measurement group_id="O2" value="0.00" spread="2.96" lower_limit="-11.82" upper_limit="8.33"/>
                    <measurement group_id="O3" value="0.00" spread="2.72" lower_limit="-9.60" upper_limit="10.31"/>
                    <measurement group_id="O4" value="-2.08" spread="3.01" lower_limit="-18.18" upper_limit="5.56"/>
                    <measurement group_id="O5" value="-18.37" spread="2.02" lower_limit="-37.50" upper_limit="0.00"/>
                    <measurement group_id="O6" value="-19.24" spread="2.17" lower_limit="-38.80" upper_limit="-4.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Quade test</method>
            <method_desc>Adjusted for Baseline value</method_desc>
            <param_type>Median Treatment Difference</param_type>
            <param_value>-18.48</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-25.28</ci_lower_limit>
            <ci_upper_limit>-11.68</ci_upper_limit>
            <estimate_desc>Median difference and 95% CI were obtained from McKean-Schrader algorithm.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Quade test</method>
            <method_desc>Adjusted for Baseline value</method_desc>
            <param_type>Median Treatment Difference</param_type>
            <param_value>-19.24</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-23.20</ci_lower_limit>
            <ci_upper_limit>-15.28</ci_upper_limit>
            <estimate_desc>Median difference and 95% CI were obtained from McKean-Schrader algorithm.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Quade test</method>
            <method_desc>Adjusted for Baseline value</method_desc>
            <param_type>Median Treatment Difference</param_type>
            <param_value>-18.37</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-24.39</ci_lower_limit>
            <ci_upper_limit>-12.35</ci_upper_limit>
            <estimate_desc>Median difference and 95% CI were obtained from McKean-Schrader algorithm.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Quade test</method>
            <method_desc>Adjusted for Baseline value</method_desc>
            <param_type>Median Treatment Difference</param_type>
            <param_value>-17.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-23.23</ci_lower_limit>
            <ci_upper_limit>-11.08</ci_upper_limit>
            <estimate_desc>Median difference and 95% CI were obtained from McKean-Schrader algorithm.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Lipoprotein (a) at Week 12</title>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Q2W</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks (Q2W) and placebo tablets once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo QM</title>
            <description>Participants received placebo subcutaneous injection once every month (QM) and placebo tablets once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Ezetimibe (Q2W)</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Ezetimibe (QM)</title>
            <description>Participants received placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Evolocumab Q2W</title>
            <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Evolocumab QM</title>
            <description>Participants received 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Lipoprotein (a) at Week 12</title>
          <population>Full analysis set</population>
          <units>percent change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="77"/>
                <count group_id="O4" value="77"/>
                <count group_id="O5" value="153"/>
                <count group_id="O6" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="2.75" lower_limit="-8.51" upper_limit="17.50"/>
                    <measurement group_id="O2" value="0.00" spread="3.26" lower_limit="-10.53" upper_limit="8.11"/>
                    <measurement group_id="O3" value="0.00" spread="2.75" lower_limit="-9.09" upper_limit="12.50"/>
                    <measurement group_id="O4" value="-2.05" spread="3.28" lower_limit="-17.19" upper_limit="8.33"/>
                    <measurement group_id="O5" value="-20.41" spread="2.04" lower_limit="-39.53" upper_limit="0.00"/>
                    <measurement group_id="O6" value="-17.82" spread="2.39" lower_limit="-38.46" upper_limit="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Quade test</method>
            <method_desc>Adjusted for Baseline value</method_desc>
            <param_type>Median Treatment Difference</param_type>
            <param_value>-20.41</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-27.76</ci_lower_limit>
            <ci_upper_limit>-13.06</ci_upper_limit>
            <estimate_desc>Median difference and 95% CI were obtained from McKean-Schrader algorithm.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Quade test</method>
            <method_desc>Adjusted for Baseline value</method_desc>
            <param_type>Median Treatment Difference</param_type>
            <param_value>-17.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-24.51</ci_lower_limit>
            <ci_upper_limit>-11.12</ci_upper_limit>
            <estimate_desc>Median difference and 95% CI were obtained from McKean-Schrader algorithm.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Quade test</method>
            <method_desc>Adjusted for Baseline value</method_desc>
            <param_type>Median Treatment Difference</param_type>
            <param_value>-20.41</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-28.13</ci_lower_limit>
            <ci_upper_limit>-12.69</ci_upper_limit>
            <estimate_desc>Median difference and 95% CI were obtained from McKean-Schrader algorithm.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Quade test</method>
            <method_desc>Adjusted for Baseline value</method_desc>
            <param_type>Median Treatment Difference</param_type>
            <param_value>-15.77</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-24.39</ci_lower_limit>
            <ci_upper_limit>-7.14</ci_upper_limit>
            <estimate_desc>Median difference and 95% CI were obtained from McKean-Schrader algorithm.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Triglycerides at the Mean of Weeks 10 and 12</title>
        <time_frame>Baseline and Weeks 10 and 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Q2W</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks (Q2W) and placebo tablets once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo QM</title>
            <description>Participants received placebo subcutaneous injection once every month (QM) and placebo tablets once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Ezetimibe (Q2W)</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Ezetimibe (QM)</title>
            <description>Participants received placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Evolocumab Q2W</title>
            <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Evolocumab QM</title>
            <description>Participants received 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Triglycerides at the Mean of Weeks 10 and 12</title>
          <population>Full analysis set</population>
          <units>percent change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="77"/>
                <count group_id="O4" value="77"/>
                <count group_id="O5" value="153"/>
                <count group_id="O6" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.89" spread="3.64" lower_limit="-18.85" upper_limit="11.24"/>
                    <measurement group_id="O2" value="4.89" spread="4.02" lower_limit="-12.71" upper_limit="31.65"/>
                    <measurement group_id="O3" value="-1.46" spread="3.60" lower_limit="-15.03" upper_limit="18.41"/>
                    <measurement group_id="O4" value="-3.97" spread="4.04" lower_limit="-17.65" upper_limit="10.38"/>
                    <measurement group_id="O5" value="-9.16" spread="2.65" lower_limit="-24.19" upper_limit="11.03"/>
                    <measurement group_id="O6" value="-15.71" spread="2.92" lower_limit="-28.20" upper_limit="6.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.72</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Quade test</method>
            <method_desc>Adjusted for Baseline value</method_desc>
            <param_type>Median Treatment Difference</param_type>
            <param_value>-5.27</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.27</ci_lower_limit>
            <ci_upper_limit>2.73</ci_upper_limit>
            <estimate_desc>Median difference and 95% CI were obtained from McKean-Schrader algorithm.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Quade test</method>
            <method_desc>Adjusted for Baseline value</method_desc>
            <param_type>Median Treatment Difference</param_type>
            <param_value>-20.59</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-30.98</ci_lower_limit>
            <ci_upper_limit>-10.20</ci_upper_limit>
            <estimate_desc>Median difference and 95% CI were obtained from McKean-Schrader algorithm.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.027</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Quade test</method>
            <method_desc>Adjusted for Baseline value</method_desc>
            <param_type>Median Treatment Difference</param_type>
            <param_value>-7.71</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.86</ci_lower_limit>
            <ci_upper_limit>1.45</ci_upper_limit>
            <estimate_desc>Median difference and 95% CI were obtained from McKean-Schrader algorithm.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.044</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Quade test</method>
            <method_desc>Adjusted for Baseline value</method_desc>
            <param_type>Median Treatment Difference</param_type>
            <param_value>-11.73</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-21.19</ci_lower_limit>
            <ci_upper_limit>-2.27</ci_upper_limit>
            <estimate_desc>Median difference and 95% CI were obtained from McKean-Schrader algorithm.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Triglycerides at Week 12</title>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Q2W</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks (Q2W) and placebo tablets once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo QM</title>
            <description>Participants received placebo subcutaneous injection once every month (QM) and placebo tablets once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Ezetimibe (Q2W)</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Ezetimibe (QM)</title>
            <description>Participants received placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Evolocumab Q2W</title>
            <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Evolocumab QM</title>
            <description>Participants received 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Triglycerides at Week 12</title>
          <population>Full analysis set</population>
          <units>percent change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="77"/>
                <count group_id="O4" value="77"/>
                <count group_id="O5" value="153"/>
                <count group_id="O6" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.91" spread="3.13" lower_limit="-18.58" upper_limit="11.46"/>
                    <measurement group_id="O2" value="2.01" spread="3.86" lower_limit="-16.62" upper_limit="33.83"/>
                    <measurement group_id="O3" value="0.00" spread="3.15" lower_limit="-13.26" upper_limit="17.54"/>
                    <measurement group_id="O4" value="-2.41" spread="3.89" lower_limit="-19.34" upper_limit="12.86"/>
                    <measurement group_id="O5" value="-8.14" spread="2.31" lower_limit="-26.14" upper_limit="10.13"/>
                    <measurement group_id="O6" value="-15.64" spread="2.78" lower_limit="-30.03" upper_limit="1.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.72</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Quade test</method>
            <method_desc>Adjusted for Baseline value</method_desc>
            <param_type>Median Treatment Difference</param_type>
            <param_value>-6.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.41</ci_lower_limit>
            <ci_upper_limit>3.95</ci_upper_limit>
            <estimate_desc>Median difference and 95% CI were obtained from McKean-Schrader algorithm.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Quade test</method>
            <method_desc>Adjusted for Baseline value</method_desc>
            <param_type>Median Treatment Difference</param_type>
            <param_value>-17.65</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-26.67</ci_lower_limit>
            <ci_upper_limit>-8.63</ci_upper_limit>
            <estimate_desc>Median difference and 95% CI were obtained from McKean-Schrader algorithm</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.027</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Quade test</method>
            <method_desc>Adjusted for Baseline value</method_desc>
            <param_type>Median Treatment Difference</param_type>
            <param_value>-8.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.54</ci_lower_limit>
            <ci_upper_limit>1.26</ci_upper_limit>
            <estimate_desc>Median difference and 95% CI were obtained from McKean-Schrader algorithm.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.044</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Quade test</method>
            <method_desc>Adjusted for Baseline value</method_desc>
            <param_type>Median Treatment Difference</param_type>
            <param_value>-13.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-21.69</ci_lower_limit>
            <ci_upper_limit>-4.77</ci_upper_limit>
            <estimate_desc>Median difference and 95% CI were obtained from McKean-Schrader algorithm.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Very Low Density Lipoprotein Cholesterol (VLDL-C) at the Mean of Weeks 10 and 12</title>
        <time_frame>Baseline and Weeks 10 and 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Q2W</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks (Q2W) and placebo tablets once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo QM</title>
            <description>Participants received placebo subcutaneous injection once every month (QM) and placebo tablets once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Ezetimibe (Q2W)</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Ezetimibe (QM)</title>
            <description>Participants received placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Evolocumab Q2W</title>
            <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Evolocumab QM</title>
            <description>Participants received 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Very Low Density Lipoprotein Cholesterol (VLDL-C) at the Mean of Weeks 10 and 12</title>
          <population>Full analysis set</population>
          <units>percent change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="77"/>
                <count group_id="O4" value="77"/>
                <count group_id="O5" value="153"/>
                <count group_id="O6" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.81" spread="3.09" lower_limit="-19.16" upper_limit="9.97"/>
                    <measurement group_id="O2" value="4.22" spread="3.70" lower_limit="-13.60" upper_limit="27.91"/>
                    <measurement group_id="O3" value="-2.69" spread="3.12" lower_limit="-16.54" upper_limit="16.67"/>
                    <measurement group_id="O4" value="-3.33" spread="3.69" lower_limit="-20.00" upper_limit="9.52"/>
                    <measurement group_id="O5" value="-8.40" spread="2.28" lower_limit="-25.43" upper_limit="10.91"/>
                    <measurement group_id="O6" value="-16.17" spread="2.65" lower_limit="-28.00" upper_limit="5.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.072</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Quade test</method>
            <method_desc>Adjusted for Baseline value</method_desc>
            <param_type>Median Treatment Difference</param_type>
            <param_value>-4.59</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.30</ci_lower_limit>
            <ci_upper_limit>2.12</ci_upper_limit>
            <estimate_desc>Median difference and 95% CI were obtained from McKean-Schrader algorithm.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Quade test</method>
            <method_desc>Adjusted for Baseline value</method_desc>
            <param_type>Median Treatment Difference</param_type>
            <param_value>-20.39</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-30.11</ci_lower_limit>
            <ci_upper_limit>-10.68</ci_upper_limit>
            <estimate_desc>Median difference and 95% CI were obtained from McKean-Schrader algorithm.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.082</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Quade test</method>
            <method_desc>Adjusted for Baseline value</method_desc>
            <param_type>Median Treatment Difference</param_type>
            <param_value>-5.71</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.13</ci_lower_limit>
            <ci_upper_limit>2.71</ci_upper_limit>
            <estimate_desc>Median difference and 95% CI were obtained from McKean-Schrader algorithm.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.044</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Quade test</method>
            <method_desc>Adjusted for Baselie value</method_desc>
            <param_type>Median Treatment Difference</param_type>
            <param_value>-12.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-22.14</ci_lower_limit>
            <ci_upper_limit>-3.54</ci_upper_limit>
            <estimate_desc>Median difference and 95% CI were obtained from McKean-Schrader algorithm.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in VLDL-C at Week 12</title>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Ful analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Q2W</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks (Q2W) and placebo tablets once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo QM</title>
            <description>Participants received placebo subcutaneous injection once every month (QM) and placebo tablets once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Ezetimibe (Q2W)</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Ezetimibe (QM)</title>
            <description>Participants received placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Evolocumab Q2W</title>
            <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Evolocumab QM</title>
            <description>Participants received 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in VLDL-C at Week 12</title>
          <population>Ful analysis set</population>
          <units>percent change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="77"/>
                <count group_id="O4" value="77"/>
                <count group_id="O5" value="153"/>
                <count group_id="O6" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.58" spread="3.67" lower_limit="-20.00" upper_limit="10.53"/>
                    <measurement group_id="O2" value="0.00" spread="3.93" lower_limit="-16.67" upper_limit="33.33"/>
                    <measurement group_id="O3" value="-0.94" spread="3.65" lower_limit="-12.32" upper_limit="12.93"/>
                    <measurement group_id="O4" value="-3.61" spread="3.87" lower_limit="-19.23" upper_limit="14.29"/>
                    <measurement group_id="O5" value="-9.52" spread="2.64" lower_limit="-26.83" upper_limit="10.34"/>
                    <measurement group_id="O6" value="-16.33" spread="2.80" lower_limit="-30.73" upper_limit="2.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.72</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Quade test</method>
            <method_desc>Adjusted for Baseline value</method_desc>
            <param_type>Median Treatment Difference</param_type>
            <param_value>-7.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-18.81</ci_lower_limit>
            <ci_upper_limit>2.92</ci_upper_limit>
            <estimate_desc>Median difference and 95% CI were obtained from McKean-Schrader algorithm.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Quade test</method>
            <method_desc>Adjusted for Baseline value</method_desc>
            <param_type>Median Treatment Difference</param_type>
            <param_value>-16.33</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-25.64</ci_lower_limit>
            <ci_upper_limit>-7.02</ci_upper_limit>
            <estimate_desc>Median difference and 95% CI were obtained from McKean-Schrader algorithm.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.082</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Quade test</method>
            <method_desc>Adjusted for Baseline value</method_desc>
            <param_type>Median Treatment Difference</param_type>
            <param_value>-8.58</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-18.10</ci_lower_limit>
            <ci_upper_limit>0.94</ci_upper_limit>
            <estimate_desc>Median difference and 95% CI were obtained from McKean-Schrader algorithm.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.044</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Quade test</method>
            <method_desc>The model includes treatment group, Baseline LDL-C level, scheduled visit and the interaction of treatment with scheduled visit as covariates.</method_desc>
            <param_type>Median Treatment Difference</param_type>
            <param_value>-12.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-20.89</ci_lower_limit>
            <ci_upper_limit>-4.54</ci_upper_limit>
            <estimate_desc>Median difference and 95% CI were obtained from McKean-Schrader algorithm.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C) at the Mean of Weeks 10 and 12</title>
        <time_frame>Baseline and Weeks 10 and 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Q2W</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks (Q2W) and placebo tablets once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo QM</title>
            <description>Participants received placebo subcutaneous injection once every month (QM) and placebo tablets once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Ezetimibe (Q2W)</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Ezetimibe (QM)</title>
            <description>Participants received placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Evolocumab Q2W</title>
            <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Evolocumab QM</title>
            <description>Participants received 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C) at the Mean of Weeks 10 and 12</title>
          <population>Full analysis set</population>
          <units>percent change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="77"/>
                <count group_id="O4" value="77"/>
                <count group_id="O5" value="153"/>
                <count group_id="O6" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.64" spread="1.26" lower_limit="-8.41" upper_limit="5.03"/>
                    <measurement group_id="O2" value="-4.67" spread="1.32" lower_limit="-10.63" upper_limit="-0.57"/>
                    <measurement group_id="O3" value="-0.92" spread="1.27" lower_limit="-10.11" upper_limit="7.29"/>
                    <measurement group_id="O4" value="0.00" spread="1.33" lower_limit="-6.98" upper_limit="8.68"/>
                    <measurement group_id="O5" value="3.89" spread="0.93" lower_limit="-1.35" upper_limit="11.55"/>
                    <measurement group_id="O6" value="3.81" spread="0.95" lower_limit="-2.56" upper_limit="11.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.007</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Quade test</method>
            <method_desc>Adjusted for Baseline value</method_desc>
            <param_type>Median Treatment Difference</param_type>
            <param_value>5.53</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.23</ci_lower_limit>
            <ci_upper_limit>8.84</ci_upper_limit>
            <estimate_desc>Median difference and 95% CI were obtained from McKean-Schrader algorithm.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Quade test</method>
            <method_desc>Adjusted for Baseline value</method_desc>
            <param_type>Median Treatment Difference</param_type>
            <param_value>8.48</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.53</ci_lower_limit>
            <ci_upper_limit>11.43</ci_upper_limit>
            <estimate_desc>Median difference and 95% CI were obtained from McKean-Schrader algorithm.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.013</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Quade test</method>
            <method_desc>Adjusted for Baseline value</method_desc>
            <param_type>Median Treatment Difference</param_type>
            <param_value>4.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.85</ci_lower_limit>
            <ci_upper_limit>8.78</ci_upper_limit>
            <estimate_desc>Median difference and 95% CI were obtained from McKean-Schrader algorithm.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.044</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Quade test</method>
            <method_desc>Adjusted for Baseline visit</method_desc>
            <param_type>Median Treatment Difference</param_type>
            <param_value>3.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.77</ci_lower_limit>
            <ci_upper_limit>8.39</ci_upper_limit>
            <estimate_desc>Median difference and 95% CI were obtained from McKean-Schrader algorithm.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in HDL-C at Week 12</title>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Q2W</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks (Q2W) and placebo tablets once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo QM</title>
            <description>Participants received placebo subcutaneous injection once every month (QM) and placebo tablets once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Ezetimibe (Q2W)</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Ezetimibe (QM)</title>
            <description>Participants received placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Evolocumab Q2W</title>
            <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Evolocumab QM</title>
            <description>Participants received 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in HDL-C at Week 12</title>
          <population>Full analysis set</population>
          <units>percent change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="77"/>
                <count group_id="O4" value="77"/>
                <count group_id="O5" value="153"/>
                <count group_id="O6" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.15" spread="1.43" lower_limit="-9.09" upper_limit="6.06"/>
                    <measurement group_id="O2" value="-5.27" spread="1.40" lower_limit="-11.30" upper_limit="2.33"/>
                    <measurement group_id="O3" value="-2.79" spread="1.42" lower_limit="-8.57" upper_limit="8.74"/>
                    <measurement group_id="O4" value="-1.47" spread="1.41" lower_limit="-6.67" upper_limit="8.20"/>
                    <measurement group_id="O5" value="4.76" spread="1.05" lower_limit="-2.86" upper_limit="12.82"/>
                    <measurement group_id="O6" value="4.06" spread="1.01" lower_limit="-2.68" upper_limit="11.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.007</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Quade test</method>
            <method_desc>Adjusted for Baseline value</method_desc>
            <param_type>Median Treatment Difference</param_type>
            <param_value>5.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.67</ci_lower_limit>
            <ci_upper_limit>10.16</ci_upper_limit>
            <estimate_desc>Median difference and 95% CI were obtained from McKean-Schrader algorithm.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Quade test</method>
            <method_desc>Adjusted for Baseline value</method_desc>
            <param_type>Median Treatment Difference</param_type>
            <param_value>9.33</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.32</ci_lower_limit>
            <ci_upper_limit>13.34</ci_upper_limit>
            <estimate_desc>Median difference and 95% CI were obtained from McKean-Schrader algorithm.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.013</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Quade test</method>
            <method_desc>Adjusted for Baseline value</method_desc>
            <param_type>Median Treatment Difference</param_type>
            <param_value>7.56</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.11</ci_lower_limit>
            <ci_upper_limit>12.00</ci_upper_limit>
            <estimate_desc>Median difference and 95% CI were obtained from McKean-Schrader algorithm.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.044</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Quade test</method>
            <method_desc>Adjusted for Baseline value</method_desc>
            <param_type>Median Treatment Difference</param_type>
            <param_value>5.53</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.22</ci_lower_limit>
            <ci_upper_limit>8.84</ci_upper_limit>
            <estimate_desc>Median difference and 95% CI were obtained from McKean-Schrader algorithm.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the first dose of blinded investigational product until the end of the study (up to 14 weeks).</time_frame>
      <desc>Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo Q2W</title>
          <description>Participants received placebo subcutaneous injection once every 2 weeks (Q2W) and placebo tablets once a day for up to 12 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Placebo QM</title>
          <description>Participants received placebo subcutaneous injection once every month (QM) and placebo tablets once a day for up to 12 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Ezetimibe (Q2W)</title>
          <description>Participants received placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
        </group>
        <group group_id="E4">
          <title>Ezetimibe (QM)</title>
          <description>Participants received placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
        </group>
        <group group_id="E5">
          <title>Evolocumab Q2W</title>
          <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.</description>
        </group>
        <group group_id="E6">
          <title>Evolocumab QM</title>
          <description>Participants received 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for up to 12 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="78"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Amgen Inc.</organization>
      <phone>866-572-6436</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

